Trial Profile
A Multic-Center, Open-Label Clinical Trial To Determine The Safety of ABX-EGF As Continued Treatment For Patients Who Have Benefited From and Tolerated Prior ABX-EGF Treatment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Aug 2015
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 10 Oct 2005 New trial record.